Latest Kynam Capital Management, LP Stock Portfolio
$1.62Billion– No. of Holdings #36
Kynam Capital Management, LP Performance:
2026 Q1: 3.17%YTD: 3.17%2025: 37.48%
Performance for 2026 Q1 is 3.17%, and YTD is 3.17%, and 2025 is 37.48%.
About Kynam Capital Management, LP and 13F Hedge Fund Stock Holdings
On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, Kynam Capital Management, LP reported an equity portfolio of $1.6 Billions as of 31 Mar, 2026.
The top stock holdings of Kynam Capital Management, LP are SNDX, CLDX, PCVX. The fund has invested 11.6% of it's portfolio in SYNDAX PHARMACEUTICALS INC and 11.4% of portfolio in CELLDEX THERAPEUTICS INC NEW.
The fund managers got completely rid off TYRA BIOSCIENCES INC (TYRA), CG ONCOLOGY INC and DYNAVAX TECHNOLOGIES CORP (DVAX) stocks. They significantly reduced their stock positions in WAVE LIFE SCIENCES LTD (WVE), NURIX THERAPEUTICS INC (NRIX) and BIOCRYST PHARMACEUTICALS INC (BCRX). Kynam Capital Management, LP opened new stock positions in UROGEN PHARMA LTD (URGN), LEGEND BIOTECH CORP (LEGN) and SOLENO THERAPEUTICS INC (SLNO). The fund showed a lot of confidence in some stocks as they added substantially to EVOMMUNE INC, TRAVERE THERAPEUTICS INC (TVTX) and PRELUDE THERAPEUTICS INC (PRLD).
The top stock holdings of Kynam Capital Management, LP are SNDX, CLDX, PCVX. The fund has invested 11.6% of it's portfolio in SYNDAX PHARMACEUTICALS INC and 11.4% of portfolio in CELLDEX THERAPEUTICS INC NEW.
The fund managers got completely rid off TYRA BIOSCIENCES INC (TYRA), CG ONCOLOGY INC and DYNAVAX TECHNOLOGIES CORP (DVAX) stocks. They significantly reduced their stock positions in WAVE LIFE SCIENCES LTD (WVE), NURIX THERAPEUTICS INC (NRIX) and BIOCRYST PHARMACEUTICALS INC (BCRX). Kynam Capital Management, LP opened new stock positions in UROGEN PHARMA LTD (URGN), LEGEND BIOTECH CORP (LEGN) and SOLENO THERAPEUTICS INC (SLNO). The fund showed a lot of confidence in some stocks as they added substantially to EVOMMUNE INC, TRAVERE THERAPEUTICS INC (TVTX) and PRELUDE THERAPEUTICS INC (PRLD).
Kynam Capital Management, LP Equity Portfolio Value
Last Reported on: 15 May, 2026
Kynam Capital Management, LP Annual Return Estimates Vs S&P 500
Our best estimate is that Kynam Capital Management, LP made a return of 3.17% in the last quarter. In trailing 12 months, it's portfolio return was 79.82%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| urogen pharma ltd | 40,408,100 |
| legend biotech corp | 28,515,200 |
| soleno therapeutics inc | 18,748,800 |
| candel therapeutics inc | 980,000 |
New stocks bought by Kynam Capital Management, LP
Additions
| Ticker | % Inc. |
|---|---|
| evommune inc | 237 |
| travere therapeutics inc | 202 |
| prelude therapeutics inc | 101 |
| geron corp | 97.79 |
| sutro biopharma inc | 81.94 |
| cytomx therapeutics inc. | 67.44 |
| viridian therapeutics inc | 59.24 |
| beam therapeutics inc | 50.9 |
Additions to existing portfolio by Kynam Capital Management, LP
Reductions
| Ticker | % Reduced |
|---|---|
| wave life sciences ltd | -55.5 |
| nurix therapeutics inc | -39.36 |
| biocryst pharmaceuticals inc | -39.35 |
| cogent biosciences inc | -34.51 |
| apellis pharmaceuticals inc | -9.2 |
| engene holdings inc | -9.11 |
| climb bio inc | -2.43 |
| celldex therapeutics inc new | -1.73 |
Kynam Capital Management, LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| tyra biosciences inc | -41,130,500 |
| dynavax technologies corp | -21,157,200 |
| cg oncology inc | -39,270,900 |
Kynam Capital Management, LP got rid off the above stocks
Sector Distribution
Kynam Capital Management, LP has about 90.3% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 90.3 |
| Others | 9.7 |
Market Cap. Distribution
Kynam Capital Management, LP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
- MID-CAP
- SMALL-CAP
- UNALLOCATED
- MICRO-CAP
| Category | % |
|---|---|
| MID-CAP | 44.9 |
| SMALL-CAP | 42.6 |
| UNALLOCATED | 9.7 |
| MICRO-CAP | 2.7 |
Stocks belong to which Index?
About 81.6% of the stocks held by Kynam Capital Management, LP either belong to S&P 500 or RUSSELL 2000 index.
- RUSSELL 2000
- Others
| Index | % |
|---|---|
| RUSSELL 2000 | 81.6 |
| Others | 18.4 |
Kynam Capital Management, LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Kynam Capital Management, LP
Kynam Capital Management, LP has 36 stocks in it's portfolio. About 70.3% of the portfolio is in top 10 stocks. VERA proved to be the most loss making stock for the portfolio. PCVX was the most profitable stock for Kynam Capital Management, LP last quarter.
Last Reported on: 15 May, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ALEC | alector inc | 0.26 | 2,000,000 | 4,300,000 | unchanged | 0.00 | ||
| AMRN | amarin corp plc | 0.42 | 472,382 | 6,830,640 | added | 21.35 | ||
| APLS | apellis pharmaceuticals inc | 2.05 | 825,000 | 33,189,800 | reduced | -9.2 | ||
| BCRX | biocryst pharmaceuticals inc | 3.34 | 5,680,800 | 54,081,200 | reduced | -39.35 | ||
| BEAM | beam therapeutics inc | 5.41 | 3,682,180 | 87,746,500 | added | 50.9 | ||
| BNR | burning rock biotech ltd | 1.22 | 1,227,560 | 19,790,500 | added | 23.39 | ||
| CADL | candel therapeutics inc | 0.06 | 200,000 | 980,000 | new | |||
| CGEM | cullinan therapeutics inc | 2.73 | 3,114,130 | 44,251,800 | unchanged | 0.00 | ||
| CLDX | celldex therapeutics inc new | 11.43 | 5,840,570 | 185,263,000 | reduced | -1.73 | ||
| COGT | cogent biosciences inc | 9.59 | 4,037,330 | 155,397,000 | reduced | -34.51 | ||
| CRBU | caribou biosciences inc | 0.29 | 2,503,300 | 4,756,270 | unchanged | 0.00 | ||
| CTMX | cytomx therapeutics inc. | 4.35 | 15,013,100 | 70,561,500 | added | 67.44 | ||
| DSGN | design therapeutics inc | 0.52 | 784,606 | 8,348,210 | unchanged | 0.00 | ||
| DVAX | dynavax technologies corp | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ELYM | climb bio inc | 0.42 | 1,003,340 | 6,872,890 | reduced | -2.43 | ||
| GERN | geron corp | 0.63 | 6,836,320 | 10,186,100 | added | 97.79 | ||
| IMCR | immunocore hldgs plc | 1.65 | 884,937 | 26,680,900 | added | 3.32 | ||
| KALV | kalvista pharmaceuticals inc | 2.26 | 1,820,950 | 36,655,800 | added | 0.55 | ||
| LEGN | legend biotech corp | 1.76 | 1,576,300 | 28,515,200 | new | |||
| NRIX | nurix therapeutics inc | 1.14 | 1,194,760 | 18,518,700 | reduced | -39.36 | ||